Search

FDA Approves Newly Formulated OTC Primatene Mist (epinephrine) to Treat Mild Asthma

Amphastar Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted approval of its New Drug Application (NDA) for Primatene Mist (epinephrine inhalation aerosol bronchodilator suspension), which is delivered by a metered dose inhaler (MDI) with a non-chlorofluorocarbon (CFC) propellant. Primatene Mist is the only FDA-approved asthma inhaler available without a prescription in the United States. Primatene Mist is indicated for the temporary relief of mild symptoms of intermittent asthma in people ages 12 and above.

#Approval #drug #FDA

1 view

Admin Login by RSP

Admin Login by Center Team

Dear Visitors !

Articles written by authors are their views and their presentation of ideas and knowledge. CHEARS does not claim right on write-up and authors are the real owner and are responsible for their write-up or views. Posts from CHEARS News Room are interpretations or presentation of news from various news resources. 

Posts from executive committee members are posts from CHEARS Office.  

© Center for Health Education, Awareness Resources and Services

Subscribe to Our Newsletter